echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Jingfeng Pharmaceutical Lincomycin Hydrochloride Injection was approved by the US ANDA

    Jingfeng Pharmaceutical Lincomycin Hydrochloride Injection was approved by the US ANDA

    • Last Update: 2021-03-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 15th, Jingfeng Pharmaceutical issued an announcement stating that its holding subsidiary had recently received a notice from the FDA that the abbreviated new drug application for Lincomycin Hydrochloride Injection has been approved.


    It is reported that lincomycin hydrochloride injection can be used for sensitive Staphylococcus, Streptococcus, Streptococcus pneumoniae and anaerobic bacteria as the cause of respiratory tract infections, skin and soft tissue infections, the female reproductive tract infections, abdominal infections and pelvic infections, two kinds of diseases can be injection mold according to the situation the hydrochloride alone or in combination with other antimicrobial agents.


    Induced respiratory tract infections, skin and soft tissue infections, female genital tract infections, abdominal and pelvic infections and other infections, the latter two types of disease can be injection mold or in combination with other antibacterial agents in accordance with the case of the hydrochloride alone.


    Lincomycin hydrochloride injection is used as a multi-dose sterile injection, and its development and production barriers are relatively high.
    Currently in the US domestic market sales in addition to the original drug manufacturer Pfizer, generic manufacturers only XGEN PHARMACEUTICALS INC.
    DJB one.
    According to IMS data show that lincomycin hydrochloride injection in 2018 in the US sales market in the country was $ 16 million, due to the environmental impact of the epidemic and the large US generics, with annual sales of under 2020 to $ 2.
    4 million.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.